durvalumab,tremelimumab
astrazeneca
[]
results from the phase 2 infinity trial of #tremelimumab and #durvalumab was safe and produced encouraging clinical activity in patients with #dmmr and msi-h epstein-barr virus-negative #gastric or #gej junction cancer. #gi23 
Oncology news and insights from leading researchers and cancer centers.